Overview

To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold

Status:
Completed
Trial end date:
2017-06-07
Target enrollment:
Participant gender:
Summary
This study will be conducted in adult participants with symptoms of common cold assessing if 1146A nasal spray reduces the severity of symptoms of the common cold compared to placebo. The study will also evaluate the safety of 1146A compared to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Carbopol 940